

★ SEAL OF
★ EXCELLENCE



*Certificate delivered by the European Commission,
as the institution managing Horizon 2020,
the EU Framework Programme for Research and Innovation 2014-2020*

The project proposal **718249, CorLog**

Clinical validation and new business creation for a novel biomarker panel measuring central venous pressure, central venous and right atrial oxygen contents, for remote monitoring of heart failure

Submitted under the Horizon 2020's **SME instrument phase 2**
call **H2020-SMEInst-2014-2015 (H2020-SMEINST-2-2015)** of **25 November 2015**
in the area of

Clinical research for the validation of biomarkers and/or diagnostic medical devices

by

EMKA TECHNOLOGIES

59 boulevard du Général Martial Valin
75015 Paris
France

following evaluation by an international panel of independent experts

**WAS SUCCESSFUL IN A HIGHLY COMPETITIVE EVALUATION PROCESS*
AS AN INNOVATIVE PROJECT PROPOSAL**

This proposal is recommended for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

* This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

Corina Crețu,
Commissioner for
Regional Policy

Carlos Moedas,
Commissioner for Research,
Science and Innovation

Brussels, 08/02/2016



Ref: Ares(2016)668437 - 08/02/2016

Proposal Evaluation Form

	EUROPEAN COMMISSION Horizon 2020 - Research and Innovation Framework Programme	Evaluation Summary Report
--	--	--------------------------------------

Call: H2020-SMEINST-2-2015
Funding scheme: SME instrument phase 2
Proposal number: 718249
Proposal acronym: CorLog
Duration (months): 30
Proposal title: Clinical validation and new business creation for a novel biomarker panel measuring central venous pressure, central venous and right atrial oxygen contents, for remote monitoring of heart failure
Activity: PHC-12-2015-P

N.	Proposer name	Country	Total Cost	%	Grant Requested	%
1	EMKA TECHNOLOGIES	FR	1,075,491	44.03%	1,075,491	44.03%
2	MI MEDICAL INNOVATION GMBH	DE	1,367,189	55.97%	1,367,189	55.97%
Total:			2,442,680		2,442,680	



Abstract:
 We intend to validate and commercialize the Cor/log Implant 1P2O, a system for fast and reliable monitoring of heart muscle oxygenation and hemodynamic performance in order to detect Heart Failure (HF). Wireless continuous connection to a trusted cloud allows fast doctor reaction and efficient corrective drug management. The system measures oxygen content from two heart locations as well as caval vein pressure. It is implanted by minimally invasive procedure, as a pacemaker. The targeted disease is HF, which leads to 1.8 million deaths in Europe every year. We will focus initially on diabetic patients who also suffer from heart failure complication. For those patients, implantation of our device, during up to six months, provides better drug regimen adjustment and prevents repeated stays in hospitals. This brings significant improvement to the quality of life of those patients but also to very high cost savings to the health organizations. We shall start by promoting the system on the German market where reimbursement is already accepted for this type of procedure, then expand to a selection of other European countries. One key milestones of this project will be clinical trials, which we intend to perform with the University Hospital in Heidelberg. This project is a French-German collaboration of two SMEs with proven, successful track records in biomedical and regulatory fields and new product validation. The overall key objective of the project is the creation of a joint-venture by the two consortium partners, later joined by outside investors, to market the system, expand the product line and the geographical distribution, to become a major player in the clinical implant world. On top of improved quality of life of patients and very significant cost savings to health organizations, business creation stemming from the project will create an initial 15 to 20 jobs, which will be expanded up to 150 to 200 jobs once the venture reaches the expected success.

Evaluation Summary Report

Evaluation Result

Total score: 12.44 (Threshold: 12)

Form Information

Indicative Appraisal Scale per Sub-Criterion:

- Very Good to Excellent (4.5 - 5)
- Good to Very Good (3.5 - 4.49)
- Fair to Good (2.5 - 3.49)
- Insufficient to Fair (1.5 - 2.49)
- Insufficient (0-1.49)